Drug Type Bispecific T-cell Engager (BiTE) |
Synonyms- |
Target |
Mechanism CD3 stimulants(T cell surface glycoprotein CD3 stimulants), TRBC1 inhibitors(TRBC1 inhibitors), TRBC2 inhibitors(T cell receptor beta constant 2 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
T-Cell Leukemia | Preclinical | JP | 07 Dec 2024 | |
TRBC1 positive T-Cell Lymphoma | Preclinical | JP | 07 Dec 2024 |